Skip to main content

HUTCHMED (China) Limited (HCM) Stock Forecast

Data as of Sep 20, 2026

Healthcare · Current price $13.70 (-0.87%)

Consensus Target
$15.37
Upside
+66.3%
Analysts
1
Rating
Buy(2.00)

Price Target Range

Low $13.60Consensus $15.37High $18.50
▲ Current $13.70

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

HCM vs Sector & Market

MetricHCMHealthcare AvgLarge Cap Avg
Analyst Rating2.002.262.42
Analyst Count1818
Target Upside+66.3%+22243.6%+21.5%
P/E Ratio5.143.7638.34

Revenue Estimates

PeriodLowAvgHigh#
2027-09-30$319M$319M$319M1
2027-12-30$319M$319M$319M1
2028-03-30$330M$330M$330M1
2028-06-30$291M$291M$291M1
2028-09-30$309M$309M$309M1
2028-12-30$338M$338M$338M1
2029-03-30$462M$462M$462M1
2029-06-30$462M$462M$462M1

EPS Estimates

PeriodLowAvgHigh#
2027-09-30$-0.39$-0.39$-0.391
2027-12-30$0.04$0.04$0.041
2028-03-30$1.46$1.46$1.461
2028-06-30$2.50$2.50$2.501
2028-09-30$0.10$0.10$0.101
2028-12-30$-0.01$-0.01$-0.011
2029-03-30$0.42$0.42$0.421
2029-06-30$0.14$0.14$0.141

Frequently Asked Questions

What is the analyst consensus for HCM?

The consensus among 1 analysts covering HUTCHMED (China) Limited (HCM) is Buy with an average price target of $15.37.

What is the highest price target for HCM?

The highest analyst price target for HCM is $18.50.

What is the lowest price target for HCM?

The lowest analyst price target for HCM is $13.60.

How many analysts cover HCM?

1 analysts have issued ratings for HUTCHMED (China) Limited in the past 12 months.

Is HCM a buy or sell right now?

Based on 1 analyst ratings, HCM has a consensus rating of Buy (2.00/5) with a +66.3% upside to the consensus target of $15.37.

What are the earnings estimates for HCM?

Analysts estimate HCM will report EPS of $-0.39 for the period ending 2027-09-30, with revenue estimated at $319M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.